Here
we are...
The
Group
The Catapharma Group
was formed in 1986 with the coming together of three young chemical engineers
with a strong desire to apply their technical skills to productive industrial
activity.
Dr.
Shrikant Karwa, the founder of
the Group, has, to his credit, a doctoral thesis on Principles of Liquid-phase
Catalytic Hydrogenation and a few international publications and review articles
in the same field. With no industrial experience and only his university
research as his asset, he directly ventured to transform his technological
insight into industrial reality.
Presently, the group comprises of 110
people with annual turn over of $ 7 millions. The core activity is manufacture
of pharmaceutical intermediates and fine chemicals. This is backed up by well
equipped research lab and pilot plant for development of new products and
up-gradation of existing processes.
Technological
Expertise
The Group
concentrated its efforts to master the technology of liquid-phase hydrogenation,
which included critical equipment design, and preparation of active and
selective catalysts. As on date, the Group has mastered catalyst design and
equipment design for reduction of various functional groups. The insight has
resulted into three self-sufficient manufacturing sites; erected and
commissioned by a complete in-house effort.
Manufacturing
Facilities
Sinnar, where the
Group's manufacturing sites are located, is an industrial belt, 180 kms from Mumbai (formerly
|
·
Catapharma
( · Catapharma Chemicals Pvt. Ltd. (1989) · Catapro Technologies (1994) ·
MDB
Chemicals ( |
They
have their own manufacturing sites based on catalytic hydrogenation and other
upstream / downstream unit processes. Catapro
Technologies undertakes research and development activity and manufacture low
volume specialty chemicals.
Quality
Control
The quality control
laboratory is equipped with necessary analytical techniques, which include GC,
HPLC, TLC, atomic photo-spectrometer, Karl-Fischer instrument. The stringent quality control procedure
ensures clearance of goods as promised to the customers.
Products

Presently, the
Group has established itself as a leading supplier in the Indian market for
various derivatives of piperazine, methylendioxybenzene and benzylamine. A list of products will give an overview of
the product range. The Group has the distinction of being the only manufacturer
in
Today, the list of esteemed
customers includes
|
§
Cipla |
§
Aurobindo
Pharma |
|
§
Dr.
Reddy's Laboratories |
§
Cadilla |
|
§
Wockhardt |
§
Aventis |
|
§
Matrix
Laboratories |
§
Saltigo |
|
§
Medichem |
|
|
§
Ranbaxy |
|
The
type of the customers the Group could service over the last decade speaks
volumes about the commitment of the Group to its chosen path of technological
excellence.
Presently, one third
of the Group's turnover is out of exports to 
Future
As the list of customers
grows, so does the list of products. The research and development efforts
continue and a few more products are on the anvil for commercialization. The
continued presence for last 17 years in the international market always opens up
new vistas for capitalizing on the technological strengths of the Group.
…
a commitment to technological excellence !